Intent to Announce for RPP 19-01 of MCDC OTA

This is not a Request for Prototype Proposals, but for planning purposes only. A project award will not be awarded from this announcement. The Government intends to announce one Request for Prototype Proposals (RPP 19-01) for execution of a project award(s) in support of Medical Countermeasure Systems Research and Development related to specified project requirements. The purpose of this announcement is to provide members of the Medical CBRN Defense Consortium, and industry in general, advanced notification of Government intent. On 08 April 2016, the Government entered into an Other Transaction Agreement (OTA) with one (1) consortium, the Medical CBRN Defense Consortium (MCDC), in support of Medical Countermeasure Systems related research and development prototype projects. It is the intent of the Government to make project award(s) to member(s) of the MCDC as a result of member project proposals submitted via the Request for Prototype Proposals process. RPP 19-01 The Government anticipates one (1) project for white papers and full proposals to be solicited via W15QKN-16-9-1002 - consisting of the following: 1. Development and FDA approval of a single use 10mg naloxone autoinjector to treat military personnel exposed to opioids. Please note that any Prototype Other Transaction Agreement awarded in response to the anticipated RPP (solicitation) will include the following statement relative to the potential for follow-on production: "In accordance with 10.U.S.C. 2371b(f), and upon a determination that the prototype project for this transaction has been successfully completed, this competitively awarded prototype OTA may result in the award of a follow-on production contract or transaction without the use of competitive procedures."